• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
NewslettersBrainstorm Health

CRISPR Gene-Editing Is Being Used to Fight Cancer—And May Be Safe

By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
By
Sy Mukherjee
Sy Mukherjee
Down Arrow Button Icon
November 7, 2019, 5:51 PM ET

This is the web version of Brainstorm Health Daily, Coins2Day’s daily newsletter on the top health care news. To get it delivered daily to your in-box, sign up here.

Good afternoon, readers.

A landmark U.S. Trial of CRISPR gene-editing to treat cancer patients finds that the treatment may, at the very least, be safe.

University of Pennsylvania researchers launched the early-stage safety trial in April (the first such trial in America, though others had already begun in China). And the results are, according to the scientists, “encouraging.”

Now here’s the inevitable caveat—These are extremely early trials, and they only assess safety in humans, not efficacy, for inserting cells genetically modified with CRISPR in order to treat cancer patients.

And, even on the safety front, there will be a whole lot more followup studies (and enrolled trial patients) before anything is certain. For now, though, the field’s champions have something to cheer about.

Read on for the day’s news.

Sy Mukherjee
[email protected]
@the_sy_guy

DIGITAL HEALTH

American Well snatches up Aligned Telehealth to build out virtual psychiatric services.  Telemedicine giant American Well is continuing to expand its footprint by snatching up Aligned Telehealth, a virtual care platform that focuses on psychiatric and behavioral health visits. That's significant given that the mental health professional shortage, relative to patients' needs, is even greater than the broader doctor shortage that's dogged America for years. 

INDICATIONS

Trump administration takes Gilead to court over HIV drugs. The Department of Health and Human Services (HHS) is hitting back against biotech giant Gilead, which has a portfolio of majorly popular HIV treatments including pre-exposure prophylaxis (PrEP) drug Truvada, in a patent dispute with a federal lawsuit. HHS is now claiming that the CDC's contributions to developing HIV prevention drugs Truvada and Descovy (which Gilead sells) mars the company's complaints to the U.S. Patent and Trademark Office (USPTO) regarding royalties the government feel is owed by Gilead. “HHS improperly filed for patents without alerting Gilead, despite its obligation to do so, and we have openly explained the defects in the patents since becoming aware of them," said Gilead in a statement responding to the HHS suit. (Endpoints News)

THE BIG PICTURE

Another vaping death update: 39 deaths, more than 2,000 cases. The CDC has released its latest update on vaping-related deaths and the numbers keep rising. The latest count? 2,051 confirmed cases and 30 deaths. To date, it appears most cases are related to illicit THC pods (though the full range of causes still isn't clear). (Reuters)

REQUIRED READING

How Adding A.I. To Gene Sequencing Can Help Detect Cancer Early, by Coins2Day Editors

China's Bitcoin Is No Libertarian Crypto Dream, by Adam Lashinsky

How CEOs Are Adapting to the Changing Demographics of the American Workforce, by Coins2Day Editors

Is OneCoin the Biggest Financial Fraud in History?By David Z. Morris

Sign up for other Coins2Day newsletters.

IF YOU LIKE THIS EMAIL...

Share today’s Brainstorm Health with a friend.

Did someone share this with you?Sign up here. For previous editions, click here.

For even more, check out raceAhead, Coins2Day's daily newsletter on culture in corporate America. Sign up here.

About the Author
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.